FDA, in partnership with other federal and international agencies, has taken action against websites that sell potentially dangerous, unapproved prescription drugs to US consumers.
FDA, in partnership with other federal and international agencies, has taken action against websites that sell potentially dangerous, unapproved prescription drugs to US consumers.
FDA and the US Customs and Border Protection (CBP) also conducted examinations at US-based international mail facilities, where many packages containing prescription drugs enter the US, and found that most of the examined packages contained illegal prescription drugs that had been ordered from online sources.
These actions took place in support of the 7th annual International Internet Week of Action (IIWA) sponsored by Interpol, and also known as Operation Pangea VII. During Operation Pangea VII, law enforcement, customs, and regulatory authorities from 111 countries collaborated to identify the makers and distributors of illegal drug products and medical devices that used the Internet to sell their products and remove these products from the supply chain.
Operation Pangea VII‘s coordinated efforts at mail facilities resulted in the detention or seizure of 19,618 packages containing medicines purportedly from Australia, the UK, New Zealand, and Canada. These packages contained unapproved or suspected counterfeit drugs from other countries, such as India, China, Singapore, Taiwan, Mexico, Laos, Malaysia, as well as Australia, New Zealand, and the UK.
The FDA and the CBP inspected packages at the mail facilities in Los Angeles, New York and Chicago, and detained or seized 583 packages. Preliminary findings show that certain drug products from abroad, such as insulin, estrogen, bimatoprost, human chorionic gonadotropin, tramadol, tadalafil, and sildenafil citrate were on their way to US consumers. The FDA also notified Internet service providers, domain name registrars, and related organizations that 1975 websites were selling products in violation of US Law.
Source: FDA
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.